Series 79 Underwriting & New Financing: Function 2 Deep Dive (2026)

Why does underwriting and new financing carry so much weight?

Function 1 (data collection, analysis, and valuation) is the biggest section on the Series 79, at 49% of the exam. Function 2, the subject of this article, comes in second at 27%, ahead of Function 3’s mergers and acquisitions material at 24%. That ranking makes sense once you see what an investment banking analyst actually does day to day: alongside modeling and diligence, a huge share of the job is executing new issues, from the first registration filing through the final settlement of the syndicate account.

Where Function 1 tests financial judgment (building a DCF, reading a set of comparables), Function 2 tests something closer to precise recall. The material is organized around a deal’s actual timeline, and at nearly every step there’s a specific rule attached to a specific number: how many days before pricing a restricted period starts, what percentage of the base offering a greenshoe can cover, how long a holding period runs before a restricted security can be resold. The exam rewards candidates who know these thresholds cold rather than candidates who understand the general concept but blur the exact figures.

This article follows the deal timeline in order: how a public offering gets registered and marketed, how the underwriting syndicate is built and compensated, how the new issue is priced and distributed, what happens in the weeks after pricing, and finally the exempt-securities and exempt-transactions framework that lets some offerings skip full registration altogether.

How does a registered public offering move through Section 5?

Every registered offering is governed by Section 5 of the Securities Act of 1933, which splits the process into three periods and dictates exactly what an issuer, underwriter, or dealer can do in each one.

The registration statement itself is built around two SEC regulations: Regulation S-K, which governs the narrative, non-financial disclosure (business description, risk factors, management’s discussion and analysis), and Regulation S-X, which governs the form and content of the financial statements. Once the statement is effective, the issuer delivers a final prospectus to investors, though in practice the “access equals delivery” framework lets a broker-dealer satisfy that obligation just by confirming the final prospectus is filed and available on EDGAR, rather than physically sending a copy to every customer.

Larger, established issuers get a faster path. A well-known seasoned issuer, one that meets a public float or outstanding registered debt threshold, can use shelf registration to register securities for sale on a continuous or delayed basis, then complete each actual sale (a “takedown”) by filing a short prospectus supplement rather than a brand-new registration statement. Combined with the ability to test investor interest and make certain offers even before filing, shelf registration is what lets a large issuer come to market with minimal lead time.

How is an underwriting syndicate structured, and who does what?

Once a deal is a firm commitment underwriting, the syndicate is documented through a layered set of agreements, and each layer carries a different level of risk.

The lead (managing) underwriter runs the show: negotiating with the issuer, drafting the syndicate agreements, allocating shares, setting the offering price, and later directing stabilization activity. It’s worth keeping straight that syndicate liability is several rather than joint, since the exam frequently tests this: if one syndicate member fails to place its allotment, the other members are not automatically responsible for covering that member’s shortfall.

Underwriting commitments come in several structures, and the exam tests the differences carefully:

Contingency offerings (all-or-none and mini-max) carry their own investor-protection regime. One rule makes it a prohibited, deceptive practice to represent an offering as all-or-none or mini-max unless a prompt refund is actually made when the contingency fails. A companion rule requires that investor funds collected during a contingency offering be held in a separate escrow arrangement, with an unaffiliated bank, rather than flowing into the broker-dealer’s general operating account. Together, these rules exist so that a contingency promise (sell it all, or give the money back) is enforceable rather than just a marketing phrase.

How does a new issue actually get marketed, priced, and sold?

Before a single share can be sold to the public, the lead underwriter’s banking team has to build internal consensus on the story, then take that story to investors.

The process starts internally: banking prepares a sales memo that briefs the firm’s own institutional and retail desks on the deal (structure, peer set, valuation, risks) so the internal sales force understands what it’s selling. External marketing is a separate, tightly regulated track. Once the preliminary (red herring) prospectus is filed, the issuer’s management and the banking team run a road show: one-on-one meetings, group sessions, and video conferences with prospective institutional investors, built around a presentation the banking team helped prepare.

Investors who like the pitch submit indications of interest, non-binding expressions of how many shares they want and at what price. The syndicate manager aggregates these into a demand curve, called building the book, which becomes the foundation for sizing and pricing the deal.

Once the deal prices, shares get allocated between retail demand (aggregated across the syndicate’s retail desks) and institutional demand (allocated by the lead based on account quality and history). Institutional allocations flow through a pot, and how the selling-concession credit gets split matters: in a fixed pot, the split among syndicate members follows a predetermined schedule, while in a jump-ball pot, the institutional buyer itself designates which syndicate member gets credit for its allocation, giving large institutions real influence over which desk gets rewarded for coverage.

What happens after the offering prices?

Pricing is not the end of the underwriter’s involvement. Several post-execution activities exist specifically to manage the new issue’s trading in the days and weeks that follow.

The over-allotment option (greenshoe)

Underwriters routinely oversell a deal on purpose, creating a short position they need to cover. The over-allotment option, universally called the greenshoe, is the SEC-sanctioned tool for managing that short: it lets underwriters buy additional shares from the issuer, capped at 15% of the base offering, typically within a 30-day window after the offering.

Stabilization

A stabilizing bid is a bid or purchase made specifically to peg, fix, or maintain a security’s price, and it’s almost always placed by the syndicate manager on behalf of the whole group. Three conditions define legitimate stabilization: the bid can never exceed the offering price (it can sit at or below it, never above), only one stabilizing bid can be active in the principal market at a time, and the possibility of stabilization has to be disclosed in the prospectus before the deal even prices. Bids meant to push a price above the offering price aren’t stabilization at all; they’re manipulation.

Lock-up agreements

Lock-ups are private contracts, negotiated between the underwriter and the issuer or its major shareholders, restricting insider sales for a period after the offering. The issuer itself typically agrees not to issue additional securities during the lock-up, while officers, directors, founders, and pre-IPO investors agree not to sell their existing shares. These are disclosed in the prospectus, but they are not an SEC requirement; the SEC’s only role is making sure the terms are disclosed. When the lock-up expires, a large block of previously restricted stock can hit the market at once, sometimes creating short-term price pressure as supply increases.

How can an issuer raise capital without a full registration?

Not every capital raise goes through the Section 5 registration process just described. The Securities Act carves out two separate categories of exemption, and the exam treats them as genuinely distinct concepts.

Exempt securities: intrastate offerings and Regulation A

The intrastate offering exemption lets an issuer raise capital from residents of a single state without federal registration, as long as both the issuer and the offering stay local: the issuer must be a resident of that state and satisfy a “doing business” test there (tied to where its revenue, assets, or employees are concentrated), and both offers and sales must go only to residents of that state. A modernized version of this exemption permits the issuer to make offers to out-of-state residents (including over the internet), so long as every actual sale still goes only to in-state residents. Either way, securities purchased under an intrastate exemption can only be resold to in-state residents for a set period after the sale.

Regulation A (often called “Reg A+”) is a conditional small-issues exemption with two tiers, and the differences between them are frequently tested side by side:

Both tiers are filed on Form 1-A and reviewed by the SEC, but a Regulation A offering is technically qualified, not registered, a distinction that shows up occasionally in exam phrasing.

Exempt transactions: private placements and Regulation D

The transaction-side exemption most Series 79 questions actually revolve around is the private placement, sold under the statutory exemption for transactions by an issuer “not involving any public offering.” Because that statutory language doesn’t define what counts as public, Regulation D exists as a safe harbor: it turns a vague, facts-and-circumstances standard into bright-line conditions issuers can rely on.

Every Regulation D offering, regardless of which rule it relies on, produces restricted securities and requires a Form D notice filing with the SEC within 15 days of the first sale. An issuer can also raise up to a set dollar cap under Rule 504 with fewer investor restrictions, though that path doesn’t carry the same federal preemption from state securities review that Rule 506 offerings enjoy.

Reselling restricted securities: Rule 144, Rule 144A, and Regulation S

Buying into a private placement is only half the picture. The exam also tests how a holder of restricted or control securities gets liquid without triggering a new registration requirement.

Rule 144 is the general resale safe harbor. It hinges on a holding period: six months if the issuer is a reporting company, 12 months if it isn’t. Once the holding period is satisfied, a plain non-affiliate can generally sell with few remaining conditions. An affiliate (an officer, director, or a holder of 10% or more of the company) has it harder even after the holding period runs: adequate current public information about the issuer has to be available, the sale is capped by a volume limit (the greater of a small percentage of outstanding shares or recent average trading volume), the sale has to go through a broker’s transaction or to a market maker, and a Form 144 filing is required once the sale crosses certain size thresholds.

Rule 144A takes a completely different approach, built for institutional trading rather than individual liquidity events. It lets a holder resell restricted securities to a Qualified Institutional Buyer, broadly an institution investing at least $100 million in securities of unaffiliated issuers, without any Rule 144 holding period or volume limit at all. The protective theory is investor sophistication rather than the passage of time. Rule 144A is the backbone of most institutional private-placement bond deals, frequently paired with a parallel Regulation S tranche sold to buyers outside the United States, where the exemption’s protective theory is geographic (the transaction sits entirely outside U.S. jurisdiction) rather than tied to investor sophistication or the passage of time.

How does the exam actually test this material?

Function 2 questions tend to describe a specific point in a deal’s timeline (a road show underway, a stock trading below its offering price the morning after pricing, an issuer structuring a capital raise for 40 accredited investors) and ask what’s permitted, what’s required, or which rule governs. The wrong answers are usually built by swapping in an adjacent number: quoting the greenshoe cap where the stabilization ceiling belongs, or applying Rule 144’s holding period to a Rule 144A resale that doesn’t have one.

The most efficient way to prepare is to walk a deal timeline end to end, from filing through syndicate settlement, and pin the specific rule and specific number to each stage rather than studying rules in isolation. This section also connects directly to the rest of the exam: the valuation and due-diligence work covered under collection, analysis, and evaluation of data feeds directly into how a new issue gets priced, and several of the disclosure and liability concepts here echo again once a deal moves into the M&A and restructuring material in mergers, tender offers, and financial restructuring.

When you’re ready to test yourself against this material, the Series 79 practice test draws heavily on Function 2 scenarios, since it’s the second-largest section on the exam.